Evaluating a 4‐marker signature of aggressive prostate cancer using time‐dependent AUC. Issue 16 (7th September 2015)

• Record Type: Journal Article
• Authors: Gerke, Travis A.; Martin, Neil E.; Ding, Zhihu; Nuttall, Elizabeth J.; Stack, Edward C.; Giovannucci, Edward; Lis, Rosina T.; Stampfer, Meir J.; Kantoff, Phillip W.; Parmigiani, Giovanni; Loda, Massimo; Mucci, Lorelei A.
• Is Part Of: Prostate. Volume 75:Issue 16(2015)
• Page Start: 1926
• Page End: 1933
• Publication Date: 2015-09-07
• Subjects: Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23090
• Languages: English
• ISSNs: 0270-4137

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pros23090-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>We previously identified a protein tumor signature of PTEN, SMAD4, SPP1, and CCND1 that, together with clinical features, was associated with lethal outcomes among prostate cancer patients. In the current study, we sought to validate the molecular model using time‐dependent measures of AUC and predictive values for discriminating lethal from non‐lethal prostate cancer.</p> </sec> <sec id="pros23090-sec-0002" sec-type="section"> <title>METHODS</title> <p>Using data from the initial study, we fit survival models for men with prostate cancer who were participants in the Physicians' Health Study (PHS; n = 276). Based on these models, we generated prognostic risk scores in an independent population, the Health Professionals Follow‐up Study (HPFS; n = 347) to evaluate external validity. In each cohort, men were followed prospectively from cancer diagnosis through 2011 for development of distant metastasis or cancer mortality. We measured protein tumor expression of PTEN, SMAD4, SPP1, and CCND1 on tissue microarrays.</p> </sec> <sec id="pros23090-sec-0003" sec-type="section"> <title>RESULTS</title> <p>During a median of 11.9 and 14.3 years follow‐up in the PHS and HPFS cohorts, 24 and 32 men (9%) developed lethal disease. When used as a prognostic factor in a new population, addition of the four markers to clinical variables did not improve discriminatory accuracy through 15 years of follow‐up.</p> </sec> <sec id="pros23090-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>Although the four markers have been identified as key biological mediators in metastatic progression, they do not provide independent, long‐term prognostic information beyond clinical factors when measured at diagnosis. This finding may underscore the broad heterogeneity in aggressive prostate tumors and highlight the challenges that may result from overfitting in discovery‐based research. <italic>Prostate 75:1926–1933, 2015</italic>. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>